A comparison of vasodilation mode among selexipag (NS-304; [2-{4-[(5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy}-N-(methylsulfonyl)acetamide]), its active metabolite MRE-269 and various prostacyclin receptor agonists in rat, porcine and human pulmonary arteries

Publication | Closed Access

DOI

Citations

References

2016

Year

Chiaki Fuchikami, Kohji Murakami, Koyuki Tajima, Junko Homan, Keiji Kosugi, Kazuya Kuramoto, Michiko Oka, Keiichi Kuwano

European Journal of Pharmacology

Medicinal ChemistryVasodilation ModeMedicineVascular PharmacologyPhysiologyHuman Pulmonary ArteriesClinical PharmacologyVascular BiologyPharmacotherapyActive Metabolite Mre-269PharmacologyDrug DiscoveryOxidative Stress